Effectiveness of the modified TaWai mobile application for reporting adverse drug reaction in Lao PDR: a cluster randomized controlled trial

被引:0
|
作者
Niphonh Mongkhonmath [1 ]
Phayom Sookaneknun Olson [2 ]
Panupong Puttarak [3 ]
Soulyvanh Keokinnaly [4 ]
Ratree Sawangjit [5 ]
机构
[1] Mahasarakham University,Department of Clinical Pharmacy, Faculty of Pharmacy
[2] Mahasarakham University,International Primary Care Practice Research Unit, Faculty of Pharmacy
[3] UCSI University,Faculty of Pharmaceutical Sciences
[4] Prince of Songkla University,Department of Pharmacognosy and Pharmaceutical Botany, Faculty of Pharmaceutical Sciences
[5] Prince of Songkla University,Innovation Unit for Consumer Protection in Healthcare Products (TaWai for Health Unit), Faculty of Pharmaceutical Sciences
[6] Lao PDR,Hospital Pharmacy Management Division, Ministry of Health
[7] Mahasarakham University,Clinical Trials and Evidence
关键词
TaWai mobile App; ADR reporting; Pharmacovigilance; Low/middle-income countries; Lao PDR;
D O I
10.1038/s41598-024-82474-9
中图分类号
学科分类号
摘要
Spontaneous adverse drug reactions (ADRs) reporting by health care professionals (HCPs) plays a vital role in pharmacovigilance (PV). However, under-reporting remain a major challenge worldwide, especially in low and middle-income countries, including Lao PDR. This cluster-randomized controlled trial evaluated the effectiveness of the modified TaWai mobile app for ADR reporting compared with the usual practice in hospitals. Two tertiary hospitals in Lao PDR (cluster units) were randomized into two groups: the intervention group (16 HCPs), which used the modified TaWai mobile app along with an educational workshop, and the control group (18 HCPs), which followed usual practice with the same educational workshop. The intervention group reported more ADR cases (28 vs. 3), and produced a higher number of high-quality reports (28 vs. 2) than the control group. The modified TaWai mobile app was highly rated by all participating HCPs. Questionnaire responses indicated that the tool is user-friendly, time-efficient, and well-suited for ADR reporting in hospitals in Lao PDR. In conclusion, these findings highlight the potential of the modified TaWai mobile app to enhance ADR reporting practices in hospitals, and its features make it a promising solution for strengthening PV in Lao PDR and similar settings.
引用
收藏
相关论文
共 50 条
  • [1] Adverse Drug Reaction Reporting Using a Mobile Device Application by Persons with Multiple Sclerosis: A Cluster Randomized Controlled Trial
    Gilles Defer
    Sophie Fedrizzi
    Damien Chevanne
    François Montastruc
    Anais R. Briant
    Jean-Jacques Parienti
    Laure Peyro-Saint-Paul
    Drug Safety, 2021, 44 : 223 - 233
  • [2] Adverse Drug Reaction Reporting Using a Mobile Device Application by Persons with Multiple Sclerosis: A Cluster Randomized Controlled Trial
    Defer, Gilles
    Fedrizzi, Sophie
    Chevanne, Damien
    Montastruc, Francois
    Briant, Anais R.
    Parienti, Jean-Jacques
    Peyro-Saint-Paul, Laure
    DRUG SAFETY, 2021, 44 (02) : 223 - 233
  • [3] Effect of An Educational Intervention to Improve Adverse Drug Reaction Reporting in Physicians: A Cluster Randomized Controlled Trial
    Elena Lopez-Gonzalez
    Maria T. Herdeiro
    María Piñeiro-Lamas
    Adolfo Figueiras
    Drug Safety, 2015, 38 : 189 - 196
  • [4] Effect of An Educational Intervention to Improve Adverse Drug Reaction Reporting in Physicians: A Cluster Randomized Controlled Trial
    Lopez-Gonzalez, Elena
    Herdeiro, Maria T.
    Pineiro-Lamas, Maria
    Figueiras, Adolfo
    DRUG SAFETY, 2015, 38 (02) : 189 - 196
  • [5] Effectiveness of the Med Safety mobile application in improving adverse drug reaction reporting by healthcare professionals in Uganda: a protocol for a pragmatic cluster-randomised controlled trial
    Kiguba, Ronald
    Mwebaza, Norah
    Ssenyonga, Ronald
    Ndagije, Helen Byomire
    Nambasa, Victoria
    Katureebe, Cordelia
    Katumba, Kenneth
    Tregunno, Phil
    Harrison, Kendal
    Karamagi, Charles
    Scott, Kathryn A.
    Pirmohamed, Munir
    BMJ OPEN, 2022, 12 (07):
  • [6] Mobile application for adverse drug reaction reporting by patients with relapsing remitting multiple sclerosis (vigipsep study): a national randomized controlled trial
    Peyro-Saint-Paul, L.
    Fedrizzi, S.
    Montastruc, F.
    Le Caignec, F.
    Chevanne, D.
    Parienti, J. -J.
    Defer, G.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 : S97 - S98
  • [7] A Cluster Randomized Controlled Trial to Assess an Educational Intervention to Increase Adverse Drug Reaction Reporting in Galicia (Northwest-Spain)
    Lopez-Gonzalez, M. E.
    Dominguez, M.
    Comendador, S.
    Diaz, C.
    Pineiro, M.
    Claveria, A.
    Herdeiro, M. T.
    Figueiras, A.
    DRUG SAFETY, 2012, 35 (10) : 936 - 936
  • [8] Mobile application for adverse drug reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): a national randomized controlled trial
    Fedrizzi, S.
    Peyro-Saint-Paul, L.
    Montastruc, F.
    Le Caignec, F.
    Chevanne, D.
    Parienti, J. J.
    Defer, G.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2019, 33 : 19 - 19
  • [9] Intervention to improve adverse drug reaction reporting:: A cluster-randomized trial among Portuguese pharmacists
    Herdeiro, Teresa
    Fiqueiras, Adolfo
    Pinto, Manuela
    Vaz, Inês
    Polónia, Jorge
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 : S116 - S117
  • [10] Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial
    Defer, Gilles
    Le Caignec, Florian
    Fedrizzi, Sophie
    Montastruc, Francois
    Chevanne, Damien
    Parienti, Jean-Jacques
    Peyro-Saint-Paul, Laure
    TRIALS, 2018, 19